Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today ...
CEO George Lasezkay highlighted the company's progress in advancing its suprachoroidal delivery platform, noting over 15,000 suprachoroidal injections performed to date. He announced alignment with ...
Korea JoongAng Daily on MSN
Exim Bank to inject $13.6 billion into AI sector over 5 years
The state-run Export-Import Bank of Korea (Exim Bank) said on Wednesday that it will roll out a comprehensive financial ...
ALPHARETTA, Ga., March 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to ...
ALPHARETTA, Ga., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. The National Toxicology Program, part of the National Institutes of Health, publishes ...
Emanuel Ax didn’t have much time to talk Tuesday. He conducted a masterclass in the morning, was in rehearsals into the early evening, and will continue rehearsals Wednesday before his “An Evening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback